We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

92 hedge funds and large institutions have $204M invested in Alaunos Therapeutics in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

32% more call options, than puts

Call options by funds: $4.85M | Put options by funds: $3.68M

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

4% less funds holding

Funds holding: 9692 (-4)

20% less capital invested

Capital invested by funds: $255M → $204M (-$51.2M)

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

Holders
92
Holders Change
-4
Holders Change %
-4.17%
% of All Funds
2.64%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
13
Increased
34
Reduced
25
Closed
17
Calls
$4.85M
Puts
$3.68M
Net Calls
+$1.16M
Net Calls Change
-$1.68M

TCRT Hedge Fund Activity: Q2 2014 in Review

92 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2014, worth a combined $204M — down 20% from $255M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TCRT and 13 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 34 added.

The largest buyer was Vanguard Group, adding an estimated $1.18M. The largest seller was Fidelity Investments, cutting an estimated $11.3M.

  • 92 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2014, down from 96 in Q1 2014.
  • Funds reported $204M of Alaunos Therapeutics stock for Q2 2014, down 20% quarter-over-quarter.
  • 13 funds opened new Alaunos Therapeutics positions in Q2 2014 and 17 closed out, a net change of -4 holders.
  • The largest Alaunos Therapeutics buyer in Q2 2014 was Vanguard Group, an estimated $1.18M added.
  • The largest Alaunos Therapeutics seller in Q2 2014 was Fidelity Investments, an estimated $11.3M sold.

Based on aggregated 13F filings for Q2 2014.